How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Lentivirus and AAV Transfection Reagent Market
- By Vector Type: Lentivirus-based Transfection Reagents, Adeno-Associated Virus (AAV)-based Transfection Reagents
- By Application: Gene Therapy Research, Cell Line Development, Protein Expression, Vaccine Development, Functional Genomics
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Clinical Research Laboratories
- By Product Form: Lentivirus Packaging Kits, AAV Packaging Kits, Transduction Enhancers, Purification Kits
- By Transfection Method: Chemical Transfection Reagents, Physical Transfection Methods, Viral Vector Transduction
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Lentivirus-based Transfection Reagents leads By Vector Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Lentivirus and AAV Transfection Reagent Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Vector Type 2
Application 5
End User 4
Product Form 4
Transfection Method 3
Companies profiled
Thermo Fisher Scientific
Merck KGaA (MilliporeSigma)
Lonza Group AG
SBI (System Biosciences)
Takara Bio Inc.
GenTarget Inc.
VectorBuilder Inc.
Applied Biological Materials Inc. (ABM)
GeneCopoeia Inc.
Amsbio LLC
Cell Biolabs Inc.
Vigene Biosciences
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Merck KGaA (MilliporeSigma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Lonza Group AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →SBI (System Biosciences)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Takara Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →GenTarget Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →VectorBuilder Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Applied Biological Materials Inc. (ABM)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →GeneCopoeia Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Amsbio LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cell Biolabs Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Vigene Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cyagen Biosciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Transomic Technologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →GeneScript
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,776M by 2033 · 7.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Lentivirus-based Transfection Reagents55.0
- Adeno-Associated Virus (AAV)-based Transfection Reagents45.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,265M → $2,022M · 6.0%
Europe$881.3M → $1,531M · 7.1%
Asia Pacific$804.7M → $1,336M · 6.5%
Latin America$498.2M → $878.1M · 7.3%
Middle East and Africa$383.2M → $655.7M · 6.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.342026
7.342027
7.352028
7.372029
7.382030
7.392031
7.412032
7.412033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific17.2
- Merck KGaA (MilliporeSigma)21.7
- Lonza Group AG9.7
- SBI (System Biosciences)7.8
- Takara Bio Inc.7.7
- GenTarget Inc.8.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Vector Type24.6%
Application11.4%
End User26.3%
Product Form23.2%
Transfection Method14.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.5
- Europe23.8
- Asia Pacific20.8
- Latin America13.7
- Middle East and Africa10.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 84 | 91 | 94 | 76 | 85 | 92 | 87 |
| Merck KGaA (MilliporeSigma) | 75 | 79 | 79 | 86 | 93 | 77 | 82 |
| Lonza Group AG | 69 | 72 | 80 | 88 | 69 | 72 | 75 |
| SBI (System Biosciences) | 78 | 73 | 81 | 64 | 71 | 74 | 74 |
| Takara Bio Inc. | 69 | 57 | 64 | 72 | 55 | 59 | 63 |
| GenTarget Inc. | 63 | 46 | 51 | 65 | 68 | 51 | 57 |
| VectorBuilder Inc. | 48 | 55 | 63 | 63 | 64 | 52 | 58 |
| Applied Biological Materials Inc. (ABM) | 48 | 56 | 38 | 47 | 50 | 58 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Merck KGaA (MilliporeSigma)
- Lonza Group AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Merck KGaA (MilliporeSigma) | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Lonza Group AG | − | ◐ | ✓ | ✓ | ✓ | ◐ |
| SBI (System Biosciences) | ◐ | ◐ | ✓ | − | ◐ | ✓ |
| Takara Bio Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| GenTarget Inc. | ◐ | − | − | ◐ | ✓ | − |
| VectorBuilder Inc. | − | − | ◐ | ◐ | − | − |
| Applied Biological Materials Inc. (ABM) | ◐ | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific87
2Merck KGaA (MilliporeSigma)82
3Lonza Group AG75
4SBI (System Biosciences)74
5Takara Bio Inc.63
6VectorBuilder Inc.58
7GenTarget Inc.57
8Applied Biological Materials Inc. (ABM)50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificMerck KGaA (MilliporeSigma)
Challenger2
Strong scale, closing on the leaders.
Lonza Group AGSBI (System Biosciences)
Contender3
Focused players with pockets of strength.
Takara Bio Inc.GenTarget Inc.VectorBuilder Inc.
Niche1
Specialists in a single segment or region.
Applied Biological Materials Inc. (ABM)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vector Type in North America, then scale across Lentivirus and AAV Transfection Reagent Market — a $410M beachhead inside a $5.86B market.
Beachhead (SOM)$410Mobtainable near-term
Serviceable (SAM)$2.45Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Lentivirus-based Transfection Reagents
Best fit — highest urgency & budget in Vector Type.
Economic buyer76 fit
Adeno-Associated Virus (AAV)-based Transfection Reagents
Strong fit — clear ROI and a fast path to value.
End user70 fit
Enterprise buyers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vector Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve19%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Vector Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Lentivirus and AAV Transfection Reagent Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified24%
Evaluation12%
Closed-won6%
$9.1KCAC
$39KLTV
4.3:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Lentivirus and AAV Transfection Reagent Market is a durable-growth opportunity — $1.94B by 2033, compounding at 8.4%.
TAM · 2025$1.02Btoday
TAM · 2033$1.94Bforecast
CAGR8.4%2027–2033
Cumulative$12.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.94BTotal addressable market
SAM$786MServiceable available market
SOM$155MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.4% CAGR
Demand compounds through 2033, outpacing GDP across Vector Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vector Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.94BLarge & growingTAM by 2033 at 8.4% CAGR
$786MServiceable nowreachable with today’s model
$155MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.51BBear5.5% CAGR
$1.94BBase8.4% CAGR
$2.48BBull11.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Lentivirus and AAV Transfection Reagent Market — a $7.73B market by 2033. Plan: grow share from 9.2% to 17.5%.
Market size · 2033$7.73Btotal addressable
Market CAGR6.0%2027–2033
Target share17.5%from 9.2% today
Revenue ambition$1.35Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.2% | 17.5% | Behind |
| Revenue | $695M | $1.35B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 35.6% | 42.8% | On track |
| Customer retention | 91.9% | 92.5% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vector Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vector Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $178M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Vector Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Lentivirus and AAV Transfection Reagent Market conversation — a $1.02B market you can size, segment and defend in minutes.
Market size · 2033$1.02Btotal opportunity
Growth7.5%CAGR to 2033
Addressable buyers1,206+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vector Type
Goal Grow share in Vector Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 2 mopayback period
$67K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Thermo Fisher ScientificMerck KGaA (MilliporeSigma)Lonza Group AGSBI (System Biosciences)Takara Bio Inc.GenTarget Inc.VectorBuilder Inc.Applied Biological Materials Inc. (ABM)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Lentivirus and AAV Transfection Reagent Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Lentivirus and AAV Transfection Reagent Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Lentiviral Vector Production System Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportLentiviral Vector (LVV) CDMO Services Market
Lentiviral Vector (LVV) CDMO Services Market is valued at USD 1.48 Billion in 2025 and is expec…
$1.5B market · 2025 base year
View reportLentiviral Packaging Services Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportLentiviral Packaging Kit Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportLentigo Maligna Melanoma Therapeutic Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportLens Transmission Meter Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportLens Thickness Gauge Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportLens Testing Equipment Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportLens Refractometer Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportLenses for Orthokeratology Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportLenses for Medical Testing Instruments Market
Market size, share, segmentation and regional forecast.
$707M market · 2025 base year
View reportLens Electron Microscope Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.